Abstract
BoNT/B and TeNT cleave substrate VAMP2 at the same scissile bond, yet these two toxins showed different efficiency on substrate hydrolysis and had different requirements for the recognition of P2′ site of VAMP2, E78. These differences may be due to their different composition of their substrate recognition pockets in the active site. Swapping of LC/T S1′ pocket residue, L230, with the corresponding isoleucine in LC/B increased LC/T activity by ∼25 fold, while swapping of LC/B S1′ pocket residue, S201, with the corresponding proline in LC/T increased LC/B activity by ∼10 fold. Optimization of both S1 and S1′ pocket residues of LC/T, LC/T (K168E, L230I) elevated LC/T activity by more than 100-fold. The highly active LC/T derivative engineered in this study has the potential to be used as a more effective tool to study mechanisms of exocytosis in central neuron. The LC/B derivative with elevated activity has the potential to be developed into novel therapy to minimize the impact of immunoresistance during BoNT/B therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
